Received Jan 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | 6315MF0020 | OT / RA |
the patient was inadvertently administered an expired dose of Nuvaxovid today with no adverse event; Initial information received on 20-Jan-2026 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 73 years old male patient who inadvertently administered an expired dose of NVX-COV2373 (ORIGINAL) adjuvanted vaccine [Nuvaxovid] with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included influenza vaccine INACT split 3V (Fluzone high dose) for immunisation. On 20-Jan-2026, the patient received 0.5 ml of suspect NVX-COV2373 (ORIGINAL) adjuvanted vaccine Injection (Unknown strength), frequency once with lot 6315MF0020 and expiry date 31-DEC-2025 via intramuscular route in the right deltoid for Immunization with no reported adverse event (Expired product administered) (Latency same day). Action taken: Not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
FLUZONE HIGH DOSE